09.11.12
Enzymotec Ltd., Kfar Baruch, Israel, has announced an approved strategy for clinical trials of its lipid-based ingredient line for infant nutrition. This plan is part of a business development strategy to develop and market directly or through its affiliated companies a line of products mimicking the vital lipids found in mother’s milk, such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA). Enzymotec intends to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals in the coming months.
One of the studies recently completed was a controlled clinical trial on InFat. InFat is a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants’ well-being.
For further information: www.enzymotec.com
One of the studies recently completed was a controlled clinical trial on InFat. InFat is a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants’ well-being.
For further information: www.enzymotec.com
